Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

CD24 Protein-VLP (AA 26-57)

CD24 Spezies: Cynomolgus Wirt: HEK-293 Cells VLP > 90 % as determined by HPLC ELISA, Imm, Func, SPR Active
Produktnummer ABIN7448155
  • Target Alle CD24 Proteine anzeigen
    CD24 (CD24 Molecule (CD24))
    Protein-Typ
    VLP
    Biologische Aktivität
    Active
    Proteineigenschaft
    AA 26-57
    Spezies
    • 21
    • 5
    • 3
    • 1
    Cynomolgus
    Quelle
    • 21
    • 3
    • 3
    • 2
    • 1
    HEK-293 Cells
    Applikation
    ELISA, Immunogen (Imm), Functional Studies (Func), Surface Plasmon Resonance (SPR)
    Verwendungszweck
    Cynomolgus CD24 Protein-VLP
    Sequenz
    Ser26-Gly57
    Produktmerkmale
    Recombinant Cynomolgus CD24 Protein-VLP is expressed from HEK293.It contains Ser26-Gly57.
    Reinheit
    > 90 % as determined by HPLC
    Sterilität
    0.22 μm filtered
    Endotoxin-Niveau
    Less than 1EU per μg by the LAL method.
    Top Product
    Discover our top product CD24 Protein
  • Applikationshinweise
    • Antibody Discovery: Immunization, Screening, Functional Characterization
    • Affinity determination: ELISA, SPR
    • In vivo pharmacokinetic analysis
    • CMC method development
    • CAR-T Positive Rate Detection
    • Blood sample determination: ELISA
    Kommentare

    Virus-like particles (VLPs) are formed from the outer capsid protein of a virus and are tiny nanoparticles formed by the automatic assembly of one or more capsid proteins. VLPs do not contain viral infectious genomes, so they are relatively safe during production operations. The SAMS™ protein engineering platform has been used to express a series of biotinylated, non-biotinylated, and fluorescently-labeled VLP-displayed antigens. They are suitable for SPR, ELISA, CAR-T positive rate detection, and other experimental scenarios.

    Virus-Like Particles (VLPs) are highly immunogenic, meaning that they can elicit a strong immune response in the host. VLPs are recognized by the immune system and are taken up by antigen-presenting cells (APCs) such as dendritic cells. Once taken up by APCs, VLPs are processed and presented to T cells, which can trigger the activation of B cells to produce antibodies against the displayed antigen. Because VLPs resemble the structure and composition of native viruses, they are highly effective at inducing both humoral and cellular immune responses.

    Generally, VLPs range in size from approximately 20 to 200 nanometers (nm). Compared to a cell-based immunization approach, their smaller size can optimize the immune response to target the specific antigen displayed on the surface of the engineered VLPs.

    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Buffer
    Supplied as 0.22μm filtered solution in PBS ( pH 7.4). Notice: If you need it for immunization, Do Not use any adjuvant.
    Lagerung
    -80 °C
    Informationen zur Lagerung
    Valid for 12 months from date of receipt when stored at -80°C., Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
    Haltbarkeit
    12 months
  • Target
    CD24 (CD24 Molecule (CD24))
    Andere Bezeichnung
    CD24 (CD24 Produkte)
    Synonyme
    CD24A Protein, Cd24a Protein, CD24 molecule Protein, CD24 Protein, Cd24 Protein
    Hintergrund
    CD24 is a sialoglycoprotein expressed at the surface of most B lymphocytes and differentiating neuroblasts. It is also expressed on neutrophils and neutrophil precursors from the myelocyte stage onwards. The potential for targeting CD24 in cancer therapy seems promising, as CD24 is overexpressed in many human cancers.
    Molekulargewicht
    3.8 kDa.
    NCBI Accession
    XP_015304503
    Pathways
    Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Activated T Cell Proliferation
Sie sind hier:
Kundenservice